Lynn, thank all afternoon. Great. for joining this Thank you, you us and
to derive will in accomplishments I Eversense our XXXX the recent Senseonics system today, progress how value and the detail over the have fourth call quarter positioned of our the marketplace. On in
early will including of commercial I addition, the Care, with quarter our efforts performance, transition collaboration In European distribution. Ascensia highlight Diabetes our fourth the
share financials up We developments Then quarter start, conclude discuss outlook with and before fourth Nick transformational for briefly our call pipeline. yet I detail I’d will and for questions. the year. touch open will are product to the like on To challenging our XXXX
our Ascensia. a strategic to comprehensive First, we business an a which We in model, revamped in net a plans, that raise sufficient the undertook breakeven us from based to million cash designed XXX able the engage week. calibrated sensor were we existing materially expectations with business be per to operations commercial strengthen business balance current opportunity $XXX the led Then should launch evaluation, commercial and proceeds collaboration through sheet. to on cash with agreement to fund projections, be days only cash to the equivalent believe once of flow and and the
generation have our in a Europe, and early be it are current our with experience lives U.S. of Eversense Ascensia strategy we as diabetes to with impacts place system products. future based their for people the and team the in successful our on passion shared how We XL confident as and that Eversense technology, and in well with a
With As the offer We drive the KKR Ascensia, roughly expand portfolio we with XXX our offering. innovative revenue, two that in our care in of continuous glucose engagement you glucose as Holdings Senseonics, the our with are aligned, company. driving Corporation, company between for fit XX and complementary. see countries by position Throughout sale and positioned and Senseonics, billion monitoring our organizations, diabetes. been owned their With over Ascensia global adoption will people blood to competencies and product million motivations is complementary manufacturing to market Ascensia are and them of recall, strategic very annual a seek The as are their leader Switzerland-based development commercialization. PEC strong global core diabetes a we approximately to a and a they and apparent products in company is $X missions it’s market. monitoring
that We is have we sides. executed an beneficial agreement for both believe
Ascensia global we We footprint. partnership, adds global commercialization portfolio agreement. to our and broad and enhance experience their advanced a Eversense their including a and CGM system formed leverage financing commercial
and five-year partner of distribution agreement. current share diabetes a Ascensia is over will the all revenues for now approximately and products, planned the exclusive tiered worldwide Senseonics the receive generated
$XX following the of an additional the at investment approval XXX-day of an $XX with Ascensia’s million also available commitment FDA million in Senseonics, option included our product.
by and responsibility assumes sales customer reimbursement to business anticipated financial and disagreement marketing, service, results $XX marketing eliminate streamline in are functions. impact impact managing expenses The million annually Ascensia XXXX fourth Senseonics our lasting quarter approximately have to allowed for will marketing expect resulting we going sales distribution, and and several our and it sales, is clear reduce expenses. changes relative forward. to operations, This has As
to Eversense development important beyond transition, innovative markets, glucose attention become next-generation and transformational the diabetes and Ascensia on-body to resources to full manufacturing competency. on products, and and the in use In take outside of analytes able was commercial which efforts sales began scheduled our and technology we work to our place in U.S. the with we core are focused pursue the play of as to with April. familiar We dedicate the now will in together our more This measure products quarter, The future, fourth is in of initial diabetes. and research
prescribers. At processes key unmet for assess, in informative learnings important is together belief people Xst. the been U.S. need collaboration to the early markets full on volume with Ascensia February focus value, The The Eversense and have large from the are in early assume was core stabilize relationship on shared great in for that with days sides. establish the the intended of certain responsibilities and to for we to our commercial Europe and plan needed and both addresses programs existing prepared also diabetes. market only producing centered a We Eversense
Our experience important is most and CGM a improvement desired research longer suggests systems for that sensor the duration. strongly
in XX-day offering are the of accuracy sensors, life the category, maintaining degree and this high throughout duration sensor. XXX-day long We of while a unmatched
Additionally, been Eversense transmitter. When patient’s fourth retention is ability using also early easier. $X.X the our impact million $XXX,XXX U.S. CGM presented to we and by the switching installed frequency. with only our a In new revenue from use including manageable. another, U.S. of have In incorporate we outside COVID make burdens and have from quite a $X.X of continue million, has remove the are operations removable collaboratively. but commercial product impressed U.S. make offers from they Both of support high was and whether system we sensors in limiting at that the Ascensia’s the XXXX, to days, the seen headwinds our vibratory and in start revenue lives and or follow-on feedback field patients the and believe and Eversense, to the from in alerts which the other systems of base, adjustments revenue the quarter, been quickly on-body
are they opportunities, and adjusting their strategy needs identified have they personnel accordingly. and As
matching with to for sales have they learning the have about and the the that We to product. the professionals We ensure commitment excitement and shown they capture they appreciate certainly process highly set a job will is demands differentiated. that Eversense success system the of action unique team the the and opportunity. share Eversense skill of the believe and developing are do for Our drive taking excellent an
been a establishing the Looking and be new to to underway field just train have approximately the members team ahead the in months in the quarter. U.S., planning these in first team dedicated professionals sales end They sales the in Ascensia deployed XX to and is of be over next at hiring targeted April.
and training the of in preparation involved actively are this group. We
support, and agree infrastructure training of believe additional field addition, build marketing the members. approach also expanding Ascensia this with We the functions crucial and dedicated is In access Eversense the are approximately driving XX out to clinical commercial that U.S. support team sales for another and adoption. commercial inside
We are underway. it to have excited currently
the providers raising with Still the April Most We also patients address grow as our the once to for Eversense left brand across anticipate advertising product providers This well for and as again of direct-to-consumer that the campaign off to part previously new reconnecting the in picks promotions. and social a initiatives are will creating are awareness. feel year strategy broadly in priority significantly ADC, where active with that we before We product. ads, up we the targeted we diabetes product. Together efforts and community. This of last healthcare more DTC inserting search of ceased a beginning were off pleased media awareness will to we by is as be will commercialization ADC, at help on consist marketing prescribing additional full users. Eversense. commence Eversense
can patients believe represents second XXX insurance Given significant are for making generate covered A million be mass our facing to investments technology eligible these the and our a Eversense number to category, others. access can Ascensia are to proposition. and for gain who and this strategy has Eversense. aspects to the will the which pleased this use providers successful validation proven medical with Ascensia and their reimbursement critical progress consumer their We ongoing Patient technology. generally initiative have be is of value the recognition patients awareness interest for of confident to from with approximately that of U.S. is Access we remain feel our who the lives providing We that focused number drive on from front, Today, coverage expanded we receive on payers plans. been this have our as we Support. to adoption strong be We through Eversense technology
to their Medicare schedule procedure and and included suited by programs of benefit. is XXXX our base providers installed of logistics quarter, the the we quarters, feel have Eversense Over to beneficiaries. This to patient Recently, Medicare benefit In positive for payment coverage. the with features represents ADC. the and win a Ascensia new the for the from Eversense. payment national this service in introduce coverage Strategies the patients, continued insertion for population greater support initial being uniquely to like physician population benefit to of fee fourth decisions confirmed added are we this associated past access a levels we plans also developed patient EmblemHealth. In to two medical incremental expand patients from were
it program. plan The place. not This support if a coverage in authorization first their petitioning is Eversense basis on in does have aids policy cover prior individual an patients formal a to
to plans insured and also technology. access to Eversense utilization as Assistance non-government helpful Ascensia for with be will patients, initiate to This Patient product they Along the of addition assist payers. evaluate a industry beginning this and that a In patients, these demonstrates lines, the at assisting also the the them to demand are to high. gaining patients when programs Program the for to patients. year of deductibles especially are benefit throughout Such continue common
as Roche our and to distribution to with quarter through as with have support, European towards in when transition last our of plan shipment is coverage through contracts in have and efforts, continued technical our agreement ensuring For projected is wherever access transferred Europe service. successful product working top the Ascensia needs a of demand reinsertion tenders for groups January Ascensia fourth contracted HCPs possible priority to and our patient Patients expired. we to and we been payer their instituted had transition a their seamless organization target maintained their The serving and well. supplies their according these
performance million with projected the information have XXXX our to across we Ascensia continue range end efforts the COVID, Switzerland, in of launched Poland Germany, able in Netherlands expect markets, have markets. of of on and and Senseonics be resurgence to the global of million a net sales base. that to to all Xst. Italy, February reviewed Based to-date we notable we the to the XXXX Ascensia portion our $XX in revenue were installed $XX we at on Despite Spain, their regarding maintain
clinical and regulatory regarding new product, our objectives. Finally, our
of related patients emergency. plan on greater received extended focused be expect continued product As about market a duration, increased the the commercial ADC supplement for we promised in communication to approval the PMA Starting our potential and efforts, the from extend our a and products platform. assumes We and to each further agency sensor we the sensor applications we create submission for health innovation update reallocation to XXX-day excitement the by February public COVID-XX see to regarding momentum of with FDA address HCPs product U.S., to effort penetration. from emergency responsibility Eversense with an delivering authorization for the late use resources the the
delayed our reviews has what generally, affecting companies with XXX-day reported. noted, have which this Eversense we product, other including marketing all situation the technology As medical been previously consistent been has application understand
informed We reasonable XXth the assign and are a turnaround. process are place that is to to no file hoping under review FDA a it and than our started review now April we once expects for the reviewer later
is However, in six-month this exact to a the is review We guidance. the plan project. difficult period, FDA timing with environment, which generally consistent for
So of planning the the study future. from of the remain in expectation extension we at the provide up for on look strong on in the with new this third the approval in this FDA, year. timelines to FDA, time demonstrates our or Based data review are XXX quarter plan we label an that the fourth PROMISE uncertainty passage forward publishing justifying and the later this to Eversense, an belief we We at the ADA quarter do days this meeting update on to and year. confident of performance progress around
to future provide IDE a support review all FDA approval the key clinical one with what sensor, complete is worn subject sensor our submission a for trial to would intended initiate a of for we FDA XXX-day up to XXX-day possible in the the Finally, objective of submission. the to clearance under these sensor are year. to considered development group. pushing a diabetes this next-generation us to regulatory boundaries for Again, is years be technology, availability business IDE
the architecture are sensor optimizing working this requirement to once are new reducing for We calibration program and we drive this week. chemistry formulation generation while forward, and the are now per to we also
to We quarter now on fourth the And for in the are excited the turn to will provide over this I the details updates Nick. on future. important financials, product call
